ATXI
Avenue Therapeutics, Inc.
Biotechnology
Market Cap$2M
5Y Perf.-100.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
ATXI vs PCRX
Revenue, margins, valuation, and 5-year total return — side by side.
PCRX
Pacira BioSciences, Inc.
Drug Manufacturers - Specialty & Generic
Market Cap$932M
5Y Perf.-46.1%
ATXI vs PCRX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ATXI | PCRX |
|---|---|---|
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic |
| Market Cap | $2M | $932M |
| Revenue (TTM) | $1M | $735M |
| Net Income (TTM) | $-4M | $9M |
| Gross Margin | 100.0% | 60.2% |
| Operating Margin | -279.8% | 3.4% |
| Forward P/E | — | 8.6x |
| Total Debt | $0.00 | $454M |
| Cash & Equiv. | $3M | $159M |
ATXI vs PCRX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ATXI
PCRX
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Avenue Therapeutics… (ATXI) | 100 | 0.0 | -100.0% |
| Pacira BioSciences,… (PCRX) | 100 | 53.9 | -46.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ATXI vs PCRX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: PCRX leads in 3 of 5 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Avenue Therapeutics, Inc. is the stronger pick specifically for recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
ATXI
Avenue Therapeutics, Inc.
The Momentum Pick
ATXI is the clearest fit if your priority is momentum.
- +111.6% vs PCRX's -5.8%
Best for: momentum
PCRX
Pacira BioSciences, Inc.
The Growth Play
PCRX carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 3.6%, EPS growth 107.4%, 3Y rev CAGR 2.9%
- -50.0% 10Y total return vs ATXI's -100.0%
- Lower volatility, beta 0.47, Low D/E 65.6%, current ratio 4.54x
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | PCRX | 3.6% revenue growth vs ATXI's -30.5% |
| Quality / Margins | PCRX | 1.3% margin vs ATXI's -266.7% |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | ATXI | +111.6% vs PCRX's -5.8% |
| Efficiency (ROA) | PCRX | 0.7% ROA vs ATXI's -105.8% |
ATXI vs PCRX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
ATXI vs PCRX — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLPCRXLAGGINGATXI
ATXIAvenue Therapeutics, …
0leads
PCRXPacira BioSciences, I…
3leads
6 Total Categories
CATEGORYLEADERvs ATXIMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
PCRX3/5
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
PCRX4/6
Total Returns1Y, 3Y, 5Y total returns with dividends
PCRX5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
PCRX leads this category, winning 3 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
PCRX is the larger business by revenue, generating $735M annually — 523.4x ATXI's $1M. Profitability is closely matched — net margins range from 1.3% (PCRX) to -2.7% (ATXI).
| Metric | ATXIAvenue Therapeuti… | PCRXPacira BioScience… |
|---|---|---|
| RevenueTrailing 12 months | $1M | $735M |
| EBITDAEarnings before interest/tax | -$4M | $95M |
| Net IncomeAfter-tax profit | -$4M | $9M |
| Free Cash FlowCash after capex | -$2M | $133M |
| Gross MarginGross profit ÷ Revenue | +100.0% | +60.2% |
| Operating MarginEBIT ÷ Revenue | -2.8% | +3.4% |
| Net MarginNet income ÷ Revenue | -2.7% | +1.3% |
| FCF MarginFCF ÷ Revenue | -124.1% | +18.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +5.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +89.1% | -30.0% |
PCRX leads this category, winning 3 of 5 comparable metrics.
Valuation Metrics
Evenly matched — ATXI and PCRX each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | ATXIAvenue Therapeuti… | PCRXPacira BioScience… |
|---|---|---|
| Market CapShares × price | $2M | $932M |
| Enterprise ValueMkt cap + debt − cash | -$842,479 | $1.2B |
| Trailing P/EPrice ÷ TTM EPS | -0.61x | 148.06x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 8.62x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | 9.87x |
| Price / SalesMarket cap ÷ Revenue | — | 1.28x |
| Price / BookPrice ÷ Book value/share | 3.84x | 1.54x |
| Price / FCFMarket cap ÷ FCF | — | 6.82x |
Evenly matched — ATXI and PCRX each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
PCRX leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
PCRX delivers a 1.3% return on equity — every $100 of shareholder capital generates $1 in annual profit, vs $-161 for ATXI. On the Piotroski fundamental quality scale (0–9), PCRX scores 9/9 vs ATXI's 2/9, reflecting strong financial health.
| Metric | ATXIAvenue Therapeuti… | PCRXPacira BioScience… |
|---|---|---|
| ROE (TTM)Return on equity | -160.6% | +1.3% |
| ROA (TTM)Return on assets | -105.8% | +0.7% |
| ROICReturn on invested capital | — | +2.3% |
| ROCEReturn on capital employed | -9.0% | +2.8% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 9 |
| Debt / EquityFinancial leverage | — | 0.66x |
| Net DebtTotal debt minus cash | -$3M | $296M |
| Cash & Equiv.Liquid assets | $3M | $159M |
| Total DebtShort + long-term debt | $0 | $454M |
| Interest CoverageEBIT ÷ Interest expense | — | 2.37x |
PCRX leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
PCRX leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in PCRX five years ago would be worth $3,748 today (with dividends reinvested), compared to $1 for ATXI. Over the past 12 months, ATXI leads with a +111.6% total return vs PCRX's -5.8%. The 3-year compound annual growth rate (CAGR) favors PCRX at -17.5% vs ATXI's -80.7% — a key indicator of consistent wealth creation.
| Metric | ATXIAvenue Therapeuti… | PCRXPacira BioScience… |
|---|---|---|
| YTD ReturnYear-to-date | -19.8% | -3.1% |
| 1-Year ReturnPast 12 months | +111.6% | -5.8% |
| 3-Year ReturnCumulative with dividends | -99.3% | -43.9% |
| 5-Year ReturnCumulative with dividends | -100.0% | -62.5% |
| 10-Year ReturnCumulative with dividends | -100.0% | -50.0% |
| CAGR (3Y)Annualised 3-year return | -80.7% | -17.5% |
PCRX leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — ATXI and PCRX each lead in 1 of 2 comparable metrics.
Risk & Volatility
ATXI is the less volatile stock with a -0.11 beta — it tends to amplify market swings less than PCRX's 0.47 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PCRX currently trades 85.7% from its 52-week high vs ATXI's 56.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ATXIAvenue Therapeuti… | PCRXPacira BioScience… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | -0.11x | 0.47x |
| 52-Week HighHighest price in past year | $0.97 | $27.64 |
| 52-Week LowLowest price in past year | $0.15 | $18.80 |
| % of 52W HighCurrent price vs 52-week peak | +56.7% | +85.7% |
| RSI (14)Momentum oscillator 0–100 | 53.6 | 54.9 |
| Avg Volume (50D)Average daily shares traded | 3K | 694K |
Evenly matched — ATXI and PCRX each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | ATXIAvenue Therapeuti… | PCRXPacira BioScience… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold |
| Price TargetConsensus 12-month target | — | $29.50 |
| # AnalystsCovering analysts | — | 36 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +15.9% |
Insufficient data to determine a leader in this category.
Key Takeaway
PCRX leads in 3 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 2 categories are tied.
Best OverallPacira BioSciences, Inc. (PCRX)Leads 3 of 6 categories
Loading custom metrics...
ATXI vs PCRX: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is ATXI or PCRX a better buy right now?
Pacira BioSciences, Inc.
(PCRX) offers the better valuation at 148. 1x trailing P/E (8. 6x forward), making it the more compelling value choice. Analysts rate Pacira BioSciences, Inc. (PCRX) a "Hold" — based on 36 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ATXI or PCRX?
Over the past 5 years, Pacira BioSciences, Inc.
(PCRX) delivered a total return of -62. 5%, compared to -100. 0% for Avenue Therapeutics, Inc. (ATXI). Over 10 years, the gap is even starker: PCRX returned -50. 0% versus ATXI's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ATXI or PCRX?
By beta (market sensitivity over 5 years), Avenue Therapeutics, Inc.
(ATXI) is the lower-risk stock at -0. 11β versus Pacira BioSciences, Inc. 's 0. 47β — meaning PCRX is approximately -527% more volatile than ATXI relative to the S&P 500.
04Which is growing faster — ATXI or PCRX?
On earnings-per-share growth, the picture is similar: Pacira BioSciences, Inc.
grew EPS 107. 4% year-over-year, compared to 98. 8% for Avenue Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ATXI or PCRX?
Pacira BioSciences, Inc.
(PCRX) is the more profitable company, earning 1. 0% net margin versus -266. 7% for Avenue Therapeutics, Inc. — meaning it keeps 1. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PCRX leads at 4. 6% versus -279. 8% for ATXI. At the gross margin level — before operating expenses — ATXI leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — ATXI or PCRX?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is ATXI or PCRX better for a retirement portfolio?
For long-horizon retirement investors, Avenue Therapeutics, Inc.
(ATXI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 11)). Both have compounded well over 10 years (ATXI: -100. 0%, PCRX: -50. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ATXI and PCRX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.